[Featured Stock] 'DND Pharmatech' Up 10% on Second Day of Listing

On the 2nd, DND Pharmatech, which entered the KOSDAQ market, showed strong performance in the early trading session.

As of 9:39 AM on the 3rd, DND Pharmatech is trading at 40,200 KRW, up 10.14% (3,700 KRW) from the previous trading day.

Founded in 2014, DND Pharmatech is a specialized company developing chronic disease treatments using GLP-1 peptide-based therapies. The company is developing multiple innovative GLP-1-based new drugs, focusing on oral obesity treatments (DD02S, DD03), injectable MASH treatments (DD01), and degenerative brain disease treatments (NLY01). Last year, the company reported consolidated sales of 18.7 billion KRW and an operating loss of 13.5 billion KRW.

In the demand forecast for institutional investors conducted from the 12th to the 18th of last month, DND Pharmatech recorded a competition rate of 848.5 to 1 and set the public offering price at 33,000 KRW, exceeding the expected price range of 22,000 to 26,000 KRW.